Christian Brueffer
Lund University
42 Papers
88 Citations
Christian Brueffer is an academic researcher from Lund University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 8, co-authored 28 publications.
Chat about Author
Papers
The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Lao H. Saal,Johan Vallon-Christersson,Jari Häkkinen,Cecilia Hegardt,Dorthe Grabau,Christof Winter,Christian Brueffer,Man-Hung Eric Tang,Christel Reuterswärd,Ralph Schulz,Anna Karlsson,Anna Ehinger,Janne Malina,Jonas Manjer,Martin Malmberg,Christer Larsson,Lisa Rydén,Niklas Loman,Åke Borg +18 more
TL;DR: It is demonstrated that large-scale population-based collection and RNA-sequencing analysis of breast cancer is feasible and the SCAN-B Initiative should significantly reduce the time to discovery, validation, and clinical implementation of novel molecular diagnostic and predictive tests.
Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative
Christian Brueffer,Johan Vallon-Christersson,Dorthe Grabau,Anna Ehinger,Jari Häkkinen,Cecilia Hegardt,Janne Malina,Yilun Chen,Pär-Ola Bendahl,Jonas Manjer,Martin Malmberg,Christer Larsson,Niklas Loman,Lisa Rydén,Åke Borg,Lao H. Saal +15 more
- 09 Mar 2018
TL;DR: In this paper, the authors developed classifiers for five conventional biomarkers (estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), Ki67, and Nottingham histologic grade (NHG) based on tumor mRNA sequencing (RNA-seq).
169
The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
Lao H. Saal,Johan Vallon-Christersson,Jari Häkkinen,Cecilia Hegardt,Dorthe Grabau,Christof Winter,Christian Brueffer,C. Reuterswärd,Ralph Schulz,Anna Karlsson,Anna Ehinger,J. Malina,Jonas Manjer,Martin Malmberg,Christer Larsson,Lisa Rydén,Niklas Loman,Åke Borg +17 more
TL;DR: It is demonstrated that large-scale population-based collection and RNA-sequencing analysis of breast cancer is feasible and the SCAN-B Initiative should significantly reduce the time to discovery, validation, and clinical implementation of novel molecular diagnostic and predictive tests.
160
precisionFDA Truth Challenge V2: Calling variants from short- and long-reads in difficult-to-map regions
Nathan D. Olson,Justin Wagner,Jennifer McDaniel,Sarah H. Stephens,Samuel T. Westreich,Anish G. Prasanna,Elaine Johanson,Ezekiel J. Maier,Emily Boja,Omar Serang,David Jáspez,José M. Lorenzo-Salazar,Adrián Muñoz-Barrera,Luis A. Rubio-Rodríguez,Carlos Flores,Konstantinos Kyriakidis,Konstantinos Kyriakidis,Andigoni Malousi,Andigoni Malousi,Kishwar Shafin,Trevor Pesout,Miten Jain,Benedict Paten,Pi-Chuan Chang,Alexey Kolesnikov,Maria Nattestad,Gunjan Baid,Sidharth Goel,Howard Yang,Andrew Carroll,Robert Eveleigh,Mathieu Bourgey,Guillaume Bourque,Gen Li,ChouXian Ma,LinQi Tang,YuanPing Du,ShaoWei Zhang,Jordi Morata,Raul Tonda,Genís Parra,Jean-Rémi Trotta,Christian Brueffer,Sinem Demirkaya-Budak,Duygu Kabakci-Zorlu,Deniz Turgut,Özem Kalay,Gungor Budak,Kübra Narcı,Elif Arslan,Richard J. C. Brown,Ivan E. Johnson,Alexey Dolgoborodov,Vladimir Semenyuk,Amit Jain,H. Serhat Tetikol,Varun Jain,Mike Ruehle,Bryan R. Lajoie,Cooper Roddey,Severine Catreux,Rami Mehio,Mian Umair Ahsan,Qian Liu,Kai Wang,Kai Wang,Sayed Mohammad Ebrahim Sahraeian,Li Tai Fang,Marghoob Mohiyuddin,Calvin Hung,Chirag Jain,Hanying Feng,Zhipan Li,Luoqi Chen,Fritz J. Sedlazeck,Justin M. Zook +75 more
TL;DR: The precisionFDA Truth Challenge V2 aimed to assess the state-of-the-art of variant calling in difficult-to-map regions and the Major Histocompatibility Complex and new methods out-performed the 2016 Truth Challenge winners.
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
H. Dalal,Malin Dahlgren,Sergii Gladchuk,Christian Brueffer,Sofia K. Gruvberger-Saal,Lao H. Saal +5 more
TL;DR: The SCAN-B study as mentioned in this paper showed that ESR2-high tumors had favorable overall survival (p = 0.006), particularly in subgroups receiving endocrine therapy and in triple-negative breast cancer.